Immunohistochemical study of remodeling of myocardial lymphatic and blood microvascular structures in terminal heart failure: Differences between ischemic and dilated cardiomyopathy

Lymphology

Volumn 43, Issue 3, 2010, Pages 110-117

  Dashkevich, Alexey ^a   Bloch, W ^b   Antonyan, A ^b   Goebel, H ^a,d   Fries, J U W ^c   Schlensak, C ^a   Beyersdorf, F ^a   Geissler, H J ^e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d TEXAS A AND M UNIVERSITY   (United States)

^e Texas A and M University ^*

Author keywords

Angiogenesis; Cardiac microvascular remodeling; Cardiomyopathy; Heart transplants; Hemangiogenesis; Immunohistochemistry; Lymphangiogenesis; Terminal heart failure

Indexed keywords

MONOCLONAL ANTIBODY D2-40; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ANGIOGENESIS; ARTICLE; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; GRAFT RECIPIENT; HEART ASSIST DEVICE; HEART FAILURE; HEART GRAFT; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISCHEMIC HEART DISEASE; MALE; MICROVASCULATURE; PRIORITY JOURNAL;

ADULT; CARDIOMYOPATHY, DILATED; CORONARY VESSELS; FEMALE; HEART FAILURE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC SYSTEM; MALE; MICROVESSELS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VESICULAR TRANSPORT PROTEINS;

EID: 78650410104     PISSN: 00247766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bleumink, GS, AM Knetsch, MC Sturkenboom, et al: Quantifying the heart failure epidemic: Prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur. Heart J. 25 (2004), 1614-1619.
2. Liu, PP, S Mak, DJ Stewart: Potential role of the microvasculature in progression of heart failure. Am. J. Cardiol. 84 (1999), 23-26.
3. Sun, Y: Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc. Res. 81 (2009), 482-490.
4. Skobe, M, T Hawighorst, DG Jackson, et al: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7 (2001), 192-198.
5. Cursiefen, C, J Cao, L Chen, et al: Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest. Ophthalmol. Vis. Sci. 45(2004), 2666-2673.
6. Geissler, HJ, A Dashkevich, UM Fischer, et al: First year changes of myocardial lymphatic endothelial markers in heart transplant recipients. Eur. J. Cardiothorac. Surg. 29(2006), 767-771.
7. Geissler, HJ, W Bloch, S Forster, et al: Morphology and density of initial lymphatics in human myocardium determined by immunohistochemistry. Thorac. Cardiovasc. Surg. 51 (2003), 244-248.
8. Barleon, B, S Sozzani, D Zhou, et al: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87 (2006), 3336-3343.
9. Unemori, EN, N Ferrara, EA Bauer, et al: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell Physiol. 153 (1992), 557-562.
10. Gerber, HP, F Condorelli, J Park, et al: Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 272 (1997), 23659-23667.
11. Katoh, O, H Tauchi, K Kawaishi, et al: Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55 (1995), 5687-5692.
12. Tammela, T, B Enholm, K Alitalo, et al: The biology of vascular endothelial growth factors. Cardiovasc. Res. 65 (2005), 550-563.
13. Kaipainen, A, J Korhonen, T Mustonen, et al: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA 92 (1995), 3566-3570.
14. Wigle, JT, N Harvey, M Detmar, et al: An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 21 (2002), 1505-1513. (Pubitemid 34614607)
15. Jackson, DG: The lymphatics revisited: New perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc. Med. 13 (2003), 1-7.
16. Makinen, T, RH Adams, J Bailey, et al: PDZ interaction site in ephrinB2 is required for tht remodeling of lymphatic vasculature. Genes Dev. 19 (2005), 397-410. (Pubitemid 40189302)
17. Kahn, HJ, A Marks: A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab. Invest. 82 (2002), 1255-1257.
18. Dashkevich, A, W Bloch, A Antonyan, et al: Morphological and quantitative changes of the initial myocardial lymphatics in terminal heart failure. Lymphat. Res. Biol. 7 (2009), 21-27.
19. Towbin JA, NE Bowles: Dilated Cardiomyopathy: A tale of cytoskeletal proteins and beyond. J. Cardiovasc. Electrophysiol. 17 (2006), 919-926.
20. Jackson, DG: Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS 112 (2004), 526-538.
21. Lee, JY, AP Spicer: Hyaluronan: A multifunctional, megaDalton, stealth molecule. Curr. Opin. Cell Biol. 12 (2000), 581-586.
22. Mehlhorn, U, HJ Geissler, GA Laine, et al: Myocardial fluid balance. Eur. J. Cardiothorac. Surg. 20 (2001), 1220-1230.
23. Laine, GA, SJ Allen: Left ventricular myocardial edema. Lymph flow, interstitial fibrosis, and cardiac function. Circ. Res. 68 (1991), 1713-1721.